- Home
- APVO vs SONN Comparison
APVO vs SONN Comparison
Compare APVO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- SONN
- Stock Information
- Founded
- APVO 2016
- SONN N/A
- Country
- APVO United States
- SONN United States
- Employees
- APVO N/A
- SONN N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- SONN Health Care
- Exchange
- APVO Nasdaq
- SONN Nasdaq
- Market Cap
- APVO 4.1M
- SONN 3.8M
- IPO Year
- APVO N/A
- SONN N/A
- Fundamental
- Price
- APVO $3.23
- SONN $1.13
- Analyst Decision
- APVO Strong Buy
- SONN Strong Buy
- Analyst Count
- APVO 1
- SONN 1
- Target Price
- APVO $5,920.00
- SONN $20.00
- AVG Volume (30 Days)
- APVO 6.7M
- SONN 44.8K
- Earning Date
- APVO 08-07-2025
- SONN 08-13-2025
- Dividend Yield
- APVO N/A
- SONN N/A
- EPS Growth
- APVO N/A
- SONN N/A
- EPS
- APVO N/A
- SONN N/A
- Revenue
- APVO N/A
- SONN $1,000,000.00
- Revenue This Year
- APVO N/A
- SONN $5,376.22
- Revenue Next Year
- APVO N/A
- SONN N/A
- P/E Ratio
- APVO N/A
- SONN N/A
- Revenue Growth
- APVO N/A
- SONN 978.39
- 52 Week Low
- APVO $2.81
- SONN $1.08
- 52 Week High
- APVO $485.37
- SONN $10.02
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- SONN 41.84
- Support Level
- APVO $2.81
- SONN $1.10
- Resistance Level
- APVO $13.11
- SONN $1.17
- Average True Range (ATR)
- APVO 1.10
- SONN 0.06
- MACD
- APVO 0.30
- SONN 0.00
- Stochastic Oscillator
- APVO 4.08
- SONN 13.33
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.